Cargando…

MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review

The alterations of MET have been detected in non-small-cell lung cancer (NSCLC). However, survival benefit of MET inhibitors remains controversial. We performed this meta-analysis to evaluate the survival benefit of MET inhibitors combined with an epidermal growth factor receptor tyrosine kinase inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jung Han, Kim, Hyeong Su, Kim, Bum Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650440/
https://www.ncbi.nlm.nih.gov/pubmed/29088885
http://dx.doi.org/10.18632/oncotarget.20824
_version_ 1783272712404205568
author Kim, Jung Han
Kim, Hyeong Su
Kim, Bum Jun
author_facet Kim, Jung Han
Kim, Hyeong Su
Kim, Bum Jun
author_sort Kim, Jung Han
collection PubMed
description The alterations of MET have been detected in non-small-cell lung cancer (NSCLC). However, survival benefit of MET inhibitors remains controversial. We performed this meta-analysis to evaluate the survival benefit of MET inhibitors combined with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) or standard chemotherapy in patients with advanced or metastatic NSCLC. A systematic computerized search of the electronic databases was carried out. From seven studies, 2,577 patients were included in the meta-analysis. Compared with patients in the placebo group, patients who received an additional MET inhibitor did not show significantly improved progression-free survival (hazard ration (HR) = 0.92 [95% confidence interval (CI): 0.79–1.08], P = 0.33) and overall survival (HR = 1.0 [95% CI: 0.90–1.11], P = 0.97). In the subgroup analysis, patients with MET-high NSCLC tended to show longer survival when treated with an additional MET inhibitor than those in the placebo group (HR = 0.76, [95% CI: 0.58–1.01], P = 0.06). In conclusion, this meta-analysis indicates that the addition of a MET inhibitor to an EGFR TKI or chemotherapy has no survival benefit over placebo in patients with advanced or metastatic NSCLC. Although patients with MET-high tumor tended to show better survival, further studies to explore more specific biomarkers are warranted to identify ideal candidates for MET inhibitors in NSCLC.
format Online
Article
Text
id pubmed-5650440
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56504402017-10-30 MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review Kim, Jung Han Kim, Hyeong Su Kim, Bum Jun Oncotarget Meta-Analysis The alterations of MET have been detected in non-small-cell lung cancer (NSCLC). However, survival benefit of MET inhibitors remains controversial. We performed this meta-analysis to evaluate the survival benefit of MET inhibitors combined with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) or standard chemotherapy in patients with advanced or metastatic NSCLC. A systematic computerized search of the electronic databases was carried out. From seven studies, 2,577 patients were included in the meta-analysis. Compared with patients in the placebo group, patients who received an additional MET inhibitor did not show significantly improved progression-free survival (hazard ration (HR) = 0.92 [95% confidence interval (CI): 0.79–1.08], P = 0.33) and overall survival (HR = 1.0 [95% CI: 0.90–1.11], P = 0.97). In the subgroup analysis, patients with MET-high NSCLC tended to show longer survival when treated with an additional MET inhibitor than those in the placebo group (HR = 0.76, [95% CI: 0.58–1.01], P = 0.06). In conclusion, this meta-analysis indicates that the addition of a MET inhibitor to an EGFR TKI or chemotherapy has no survival benefit over placebo in patients with advanced or metastatic NSCLC. Although patients with MET-high tumor tended to show better survival, further studies to explore more specific biomarkers are warranted to identify ideal candidates for MET inhibitors in NSCLC. Impact Journals LLC 2017-09-11 /pmc/articles/PMC5650440/ /pubmed/29088885 http://dx.doi.org/10.18632/oncotarget.20824 Text en Copyright: © 2017 Kim et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Meta-Analysis
Kim, Jung Han
Kim, Hyeong Su
Kim, Bum Jun
MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review
title MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review
title_full MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review
title_fullStr MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review
title_full_unstemmed MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review
title_short MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review
title_sort met inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review
topic Meta-Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650440/
https://www.ncbi.nlm.nih.gov/pubmed/29088885
http://dx.doi.org/10.18632/oncotarget.20824
work_keys_str_mv AT kimjunghan metinhibitorsinadvancednonsmallcelllungcancerametaanalysisandreview
AT kimhyeongsu metinhibitorsinadvancednonsmallcelllungcancerametaanalysisandreview
AT kimbumjun metinhibitorsinadvancednonsmallcelllungcancerametaanalysisandreview